Basel, 23 May 2017 Reminder: Invitation to Roche Analyst Event at ASCO 2017 Monday, 5 June 2017, 5:15pm CDT We are pleased to invite you to an analyst briefing to discuss data presented on the Roche Group’s oncology products and pipeline at the American Society of Clinical Oncology Annual Meeting (ASCO) in Chicago (2 –... Read more
Basel, 23 May 2017 FDA approves Roche’s Actemra/RoActemra (tocilizumab) for giant cell arteritis Actemra/RoActemra is the first FDA-approved treatment for adults with giant cell arteritis (GCA) FDA previously granted Priority Review and Breakthrough Therapy Designation for Actemra/RoActemra in GCA Sixth FDA approval for Actemra/RoActemra since its US launch in 2010 Roche (SIX: RO, ROG; OTCQX:... Read more
Basel, 23 May 2017 FDA approves Roche’s Actemra/RoActemra (tocilizumab) for giant cell arteritis Actemra/RoActemra is the first FDA-approved treatment for adults with giant cell arteritis (GCA) FDA previously granted Priority Review and Breakthrough Therapy Designation for Actemra/RoActemra in GCA Sixth FDA approval for Actemra/RoActemra since its US launch in 2010 Roche (SIX: RO, ROG; OTCQX:... Read more
Basel, 18 May 2017 Invitation: Roche Analyst Event at ISTH 2017 Monday, 10 July 2017, 6:30pm CEST We kindly invite investors and analysts to participate in an analyst briefing during the International Society on Thrombosis and Hemostasis Congress (ISTH) in Berlin 8 – 13 July 2017. During the briefing, Roche will discuss new data for... Read more
Basel, 18 May 2017 Roche presents the first Phase I efficacy and safety data on CEA-TCB (CEA CD3 TCB), a novel T-cell bispecific antibody targeting solid tumours Encouraging clinical activity in metastatic colorectal cancer after failure of at least two prior chemotherapy regimens to be presented at the ASCO Annual Meeting Roche (SIX: RO, ROG;... Read more
Basel, 11 May 2017 Roche to present new data on personalised medicines and cancer immunotherapies at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting 20 Roche medicines are included in more than 190 abstracts during ASCO 2017 New pivotal results for Perjeta (pertuzumab) and Alecensa (alectinib) improve upon standards of care Early... Read more
Basel, 10 May 2017 Roche provides update on phase III study of TECENTRIQ® (atezolizumab) in people with previously treated advanced bladder cancer IMvigor211 study did not meet its primary endpoint of overall survival (OS) compared to chemotherapy The safety profile was consistent with what has been previously observed for TECENTRIQ Roche (SIX: RO, ROG; OTCQX:... Read more
Basel, 10 May 2017 Roche provides update on phase III study of TECENTRIQ® (atezolizumab) in people with previously treated advanced bladder cancer IMvigor211 study did not meet its primary endpoint of overall survival (OS) compared to chemotherapy The safety profile was consistent with what has been previously observed for TECENTRIQ Roche (SIX: RO, ROG; OTCQX:... Read more
Basel, 08 May 2017 First blood-based distributed oncology tests covering all four mutation classes Three test choices provide accurate insights into different stages and types of cancer Streamlined testing generates results in five days Roche (SIX: RO, ROG; OTCQX:RHHBY) today announced the global commercial launch of the AVENIO circulating tumor DNA (ctDNA) Analysis Kits, a... Read more
Basel, 08 May 2017 Roche launches AVENIO ctDNA Analysis Kits for Oncology Research First blood-based distributed oncology tests covering all four mutation classes Three test choices provide accurate insights into different stages and types of cancer Streamlined testing generates results in five days Roche (SIX: RO, ROG; OTCQX:RHHBY) today announced the global commercial launch of... Read more